Rheumatoid Arthritis Breakthrough - Plos Biology Rheumatoid arthritis is a painful, inflammatory type of arthritis that occurs when the body's immune system attacks itself. A new paper, published in this week's issue of PLoS Biology, reports a breakthrough in the understanding of how autoimmune responses can be controlled, offering a promising new strategy for therapy development for rheumatoid arthritis.
Source: www.medicalnewstoday.comBioReliance Introduces New Protein Array Platform - ReliArray™ - Provides Antibody Detection With Greater Speed, Sensitivity And Scalability BioReliance announces the introduction of its new protein array platform that offers greater sensitivity, reduced testing time and reliable results. The platform, brand-named ReliArray™, can simultaneously screen for four non-human pathogens in animal serum. "It is essential to researchers that they can depend on the results of serological screenings. These tests ensure that their research animals are
healthy and will keep their research results uncompromised.
Source: www.medicalnewstoday.comDeCODE Study Expands Clinical Utility Of DeCODE AF(TM) For Improving The Diagnosis Of Atrial Fibrillation And Preventing Stroke In a presentation yesterday at the American Heart Association Scientific Sessions 2008, scientists from deCODE genetics (Nasdaq:DCGN) presented data from large scale case-control studies in multiple populations that underscore the clinical utility of the deCODE AF(TM) test for improving the diagnosis and treatment of atrial fibrillation as a means to prevent stroke.
Source: www.medicalnewstoday.comResearch Identifies Predictors For Successful IVF Ferring Pharmaceuticals presented the results of a number of studies in assisted reproductive technology (ART) treatments at the 64th Annual Meeting of the American Society for Reproductive
Medicine (ASRM) in San Francisco, November 8-12, 2008. Four studies compared ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, to intramuscular (IM) progesterone-in-oil (PIO) for luteal support.
Source: www.medicalnewstoday.comGenmab A/S: Ofatumumab Pivotal CLL Data To Be Presented At ASH Genmab A/S (OMX: GEN) announced that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session.
Source: www.medicalnewstoday.comRaptor Pharmaceuticals To Collaborate With Centre Hospitalier Universitaire D'Angers For Phase II Clinical Trial In Huntington's Disease Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's").
Source: www.medicalnewstoday.comInterim Analysis Of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety For Corthera's Relaxin In Acute Heart Failure Corthera Inc. announced that an interim analysis of top-line data from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, international study, showed favorable efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure. The interim Phase II results were presented by John R. Teerlink, M.D.
Source: www.medicalnewstoday.comGSK Will Overtake Pfizer To Become World's Largest Pharmaceutical Company By 2012 - URCH Publishing There will be major changes in the global pharmaceutical market and key changes in the top ten company list by 2012, says a new report from URCH Publishing, a leading provider of pharmaceutical industry business information. The report,
Source: www.medicalnewstoday.comPotentia Pharmaceuticals' Drug Candidate For Age Related Macular Degeneration Shows Positive Safety Profile In Phase I Clinical Trial Potentia Pharmaceuticals, a privately held biotechnology company developing
medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 PM
